Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Depreciation and Depletion (2019 - 2023)

Historic Depreciation and Depletion for Marker Therapeutics (MRKR) over the last 5 years, with Q1 2023 value amounting to $800000.0.

  • Marker Therapeutics' Depreciation and Depletion rose 3333.33% to $800000.0 in Q1 2023 from the same period last year, while for Mar 2023 it was $3.0 million, marking a year-over-year increase of 3636.36%. This contributed to the annual value of $2.8 million for FY2022, which is 3333.33% up from last year.
  • Marker Therapeutics' Depreciation and Depletion amounted to $800000.0 in Q1 2023, which was up 3333.33% from $800000.0 recorded in Q4 2022.
  • In the past 5 years, Marker Therapeutics' Depreciation and Depletion registered a high of $800000.0 during Q3 2022, and its lowest value of $11000.0 during Q1 2019.
  • Over the past 5 years, Marker Therapeutics' median Depreciation and Depletion value was $500000.0 (recorded in 2021), while the average stood at $364705.9.
  • In the last 5 years, Marker Therapeutics' Depreciation and Depletion surged by 156666.67% in 2021 and then surged by 2000.0% in 2022.
  • Marker Therapeutics' Depreciation and Depletion (Quarter) stood at $30000.0 in 2019, then surged by 566.67% to $200000.0 in 2020, then skyrocketed by 150.0% to $500000.0 in 2021, then skyrocketed by 60.0% to $800000.0 in 2022, then changed by 0.0% to $800000.0 in 2023.
  • Its Depreciation and Depletion stands at $800000.0 for Q1 2023, versus $800000.0 for Q4 2022 and $800000.0 for Q3 2022.